Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, an...
HTG Molecular Diagnostics, Inc. ("HTG") is a pr...
The ONLY patented, drug free, saline free, all natural, DAILY nasal hygiene wash, ...
The ONLY patented, drug free, saline free, all ...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...
scPharmaceuticals is a clinical-stage pharmaceu...
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing ...
Clearside Biomedical, Inc. is a biopharmaceutic...
BridgeBio finds, develops, and delivers breakthrough medicines for genetic disease...
BridgeBio finds, develops, and delivers breakth...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
Join the National Investor Network and get the latest information with your interests in mind.